<DOC>
	<DOCNO>NCT00314652</DOCNO>
	<brief_summary>The objective study assess safety efficacy buprenorphine transdermal system ( 5 , 10 , 20 mg ) comparison placebo transdermal system subject osteoarthritis pain . The double-blind treatment intervention duration 28 day .</brief_summary>
	<brief_title>Safety Efficacy Buprenorphine Transdermal Delivery System Subjects With Osteoarthritis Pain .</brief_title>
	<detailed_description>Buprenorphine synthetic opioid analgesic twenty-five year international clinical experience indicate safe effective variety therapeutic situation relief moderate severe pain . Transdermal system may offer advantage currently indicate oral product include ease convenience use , improve compliance , possible reduction patient care , prolong consistent delivery drug .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>documented history and/or radiologic evidence chronic osteoarthritis hip knee . receive opioid therapy osteoarthritisrelated pain within past year experience pain inadequately control full standard dose NSAIDs . receive opioids average daily dose great 90 mg oral morphine equivalent patient receive 12 tablet capsule per day shortacting opioidcontaining product schedule surgery ( include dental ) study period involve use pre and/or postoperative analgesic anesthetic . Other protocolspecific exclusion/inclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>chronic pain</keyword>
	<keyword>opioid</keyword>
	<keyword>transdermal</keyword>
</DOC>